Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Instil Bio (TIL)
NASDAQ:TIL
Instil Bio (TIL) Stock Price & Analysis
44 Followers
TIL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.07 - $13.04
Previous Close$11.5
Volume1.41K
Average Volume (3M)12.96K
Market Cap
$74.79M
Enterprise Value-$41.69M
Total Cash (Recent Filing)$201.70M
Total Debt (Recent Filing)$85.21M
Price to Earnings (P/E)-0.6
Beta1.68
Next Earnings
Aug 09, 2024EPS Estimate
-$2.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-18.96
Shares Outstanding6,503,913
10 Day Avg. Volume14,008
30 Day Avg. Volume12,957
Standard Deviation0.21
R-Squared0.08
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)0.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$20.33Price Target Upside77.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Instil Bio News
PremiumCompany Announcements
Instil Bio Announces Board Reshuffle Following Resignation
PremiumCompany Announcements
Instil Bio Executives Secure Retention Bonus AgreementsBulls Say, Bears Say
Bulls Say
Drug Development ProgressInstil Bio, Inc. is developing innovative TIL therapies, with the CoStAR molecule potentially enhancing treatment of solid tumors.
Financial HealthInstil Bio enjoys a substantial cash runway, with expectations to fund operations well into the future, signaling financial stability.
Regulatory MilestonesThe recent Amtagvi (lifileucel) approval sets a clear regulatory precedent for TIL class therapeutics, potentially benefiting Instil Bio's pipeline.
Bears Say
Clinical DevelopmentCompany is undergoing strategic restructuring and has discontinued ITIL-306 clinical development.
Financial ForecastReducing price target to $32/share due to current market dynamics surrounding Instil shares.
Operational ChangesFollowing the change in strategy and transfer of the program to China, company has closed its UK manufacturing and clinical operations.
---
Ownership Overview
Currently, No data available
---
TIL FAQ
What was Instil Bio’s price range in the past 12 months?
Instil Bio lowest stock price was $6.07 and its highest was $13.04 in the past 12 months.
What is Instil Bio’s market cap?
Currently, no data Available
When is Instil Bio’s upcoming earnings report date?
Instil Bio’s upcoming earnings report date is Aug 09, 2024 which is in 80 days.
How were Instil Bio’s earnings last quarter?
Instil Bio released its earnings results on May 10, 2024. The company reported -$2.39 earnings per share for the quarter, missing the consensus estimate of -$2.23 by -$0.16.
Is Instil Bio overvalued?
According to Wall Street analysts Instil Bio’s price is currently Undervalued.
Does Instil Bio pay dividends?
Instil Bio does not currently pay dividends.
What is Instil Bio’s EPS estimate?
Instil Bio’s EPS estimate is -$2.98.
How many shares outstanding does Instil Bio have?
Instil Bio has 6,503,913 shares outstanding.
What happened to Instil Bio’s price movement after its last earnings report?
Instil Bio reported an EPS of -$2.39 in its last earnings report, missing expectations of -$2.23. Following the earnings report the stock price went up 3.117%.
Which hedge fund is a major shareholder of Instil Bio?
Among the largest hedge funds holding Instil Bio’s share is Baker Bros Advisors LP. It holds Instil Bio’s shares valued at N/A.
---
Instil Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.33 (77.71% Upside)
$20.33 (77.71% Upside)
Hedge Fund Trend
Decreased
By 325.1K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.35%
12-Months-Change
Fundamentals
Return on Equity
-47.71%
Trailing 12-Months
Asset Growth
-28.30%
Trailing 12-Months
Company Description
Instil Bio
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
---
TIL Stock 12 Month Forecast
Average Price Target
$20.33
▲(77.71% Upside)
Technical Analysis
Best Analysts Covering TIL
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-59.68%
reiterated a buy rating 11 days ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -59.68% per trade.
---